Skip to content
Research Article Open access CC BY 3.0

The Effect of Required Injection Numbers during the First Year on the Clinical Course of Neovascular Age-related Macular Degeneration

Abdullah Ozkaya, Ihsan Yilmaz, Zeynep Alkin, Yalcin Karakucuk, Ahmet Taylan Yazici

Ophthalmology Research: An International Journal · pp. 397–405 · Published 23 Jul 2014

10.9734/OR/2014/11667

Abstract

Aims: To evaluate the effect of injection number of ranibizumab on an as-needed treatment regimen during the first year of treatment on the clinical course of neovascular age-related macular degeneration (nAMD). Study Design:  Retrospective study. Place and Duration of Study: Beyoglu Eye Training and Research Hospital. Department of Retina, between December 2009 and December 2011. Methodology: The newly diagnosed nAMD patients who were treated with intravitreal ranibizumab on an as-needed treatment regimen with a follow-up period of at least 24 months were included in the study. The patients were divided into three groups according to the required injection numbers during the first year; group 1, 3 injections; group 2, 4-5 injections; group 3≥5 injections. Main outcome measures were the change in best corrected visual acuity (BCVA), and central retinal thickness (CRT). Secondary outcome measure was the number of injections during the second year. Results: The study included 92 eyes of 87 patients. Group 1 consisted of 14 eyes (15.2%), group 2 consisted of 30 eyes (32.6%), and group 3 consisted of 48 eyes (52.2%). The visual outcomes seemed better in group 1; however, there was not a statistically significant difference among the three groups in regards of change in BCVA at all of the time points (p=0.4 for month 6, p=0.5 for month 12, p=0.6 for month 18, p=0.6 for month 24). There was not a statistically significant difference among the three groups in regards of change in CRT at all of the time points (p=0.2 for month 6, p=0.2 for month 12, p=0.1 for month 18, p=0.6 for month 24). The mean number of injections at month 12 and 24 was statistically different among the three groups (p<0.0001 for both). Conclusion: This study did not show a relationship between injection numbers and treatment outcomes in patients with nAMD on an as-needed treatment regimen. However there was a difference among the three groups in regard of visual acuity which was not statistically significant.  

Age-related macular degeneration as-needed treatment ranibizumab AMD

References (18)

  1. 1 Ranibizumab for Neovascular Age-Related Macular Degeneration [DOI]
  2. 2 Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration [DOI]
  3. 3 A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study [DOI]
  4. 4 Epidemiology of Age-Related Macular Degeneration [DOI]
  5. 5 Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial [DOI]
  6. 6 Ranibizumab in neovascular age-related macular degeneration [DOI]
  7. 7 Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration [DOI]
  8. 8 Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration: A retrospective study of 58 patients [DOI]
  9. 9 Epidemiology of Age-related Macular Degeneration [DOI]
  10. 10 Hemorrhagic Age-Related Macular Degeneration Managed With Vitrectomy, Subretinal Injection of Tissue Plasminogen Activator, Gas Tamponade, and Upright Positioning [DOI]
  11. 11 Intravitreal ranibizumab for neovascular age-related macular degeneration patients with good baseline visual acuity and the predictive factors for visual outcomes [DOI]
  12. 12 Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients [DOI]
  13. 13 On the selectivity of photodynamic therapy of choroidal neovascularization associated with age-related macular degeneration [DOI]
  14. 14 Coût-efficacité du traitement par thérapie photodynamique à la verteporfine des membranes néovasculaires dans la dégénérescence maculaire liée à l’âge en pratique clinique en Suisse [DOI]
  15. 15 Apport de la photothérapie dynamique dans la qualité de vie des patients atteints de dégénérescence maculaire exsudative [DOI]
  16. 16 Traitement des décollements de l’épithélium pigmentaire par photothérapie dynamique, IVT de ranibizumab, sous-ténonienne de triamcinolone [DOI]
  17. 17 [Current treatment of choroidal neovascularization in age-related macular degeneration].
  18. 18 Triple therapy for the treatment of choroidal neovascularization with pigment epithelium detachment in age‐related macular degeneration [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

56

Page views

0

PDF downloads

31

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.